Event agenda

Registration & Welcome Coffee

Welcome by the Charité Representatives

ReSHAPE the immune balance - several steps forward along the path

Petra Reinke / Charité – Universitätsmedizin Berlin, Germany

Gene editing strategies to create next generation of cell-and gene therapies for clinical application

Dimitrios L. Wagner / Charité – Universitätsmedizin Berlin / Berlin Institute of Health at Charité, Germany / Baylor College of Medicine, Houston, USA

Generating and Applying Epigenomic Knowledge to Improve Therapeutic Cell Products

Julia Polansky / Berlin Institute of Health at Charité, Germany

Benefits of imaging cell-based immunotherapies

Invited Speaker: Gilbert Fruhwirth / School of Cancer and Pharmaceutical Sciences, King´s College London, UK

Next generation Treg development platform for tissue specific CAR Treg

Elmar Jäckel / Medizinische Hochschule Hannover, Germany / Ajmera Transplant Centre, University Health Network, Toronto, Canada

ID card of the cell product and therapy response monitoring

Hans-Dieter Volk / Charité – Universitätsmedizin Berlin / CheckImmune GmbH, Germany

Combination cell therapy with recipient Tregs and donor bone marrow in HLA mismatched kidney transplantation

Invited Speaker: Thomas Wekerle / Medical University of Vienna, Austria

The two study – transplantation without over immune suppression

Fadi Issa / Nuffield Department of Surgical Sciences / University of Oxford, UK

ProTreg Trial – A phase I/IIa study to investigate the safety and tolerability of Tregs as an adjunctive therapy in CD kidney recipients following anti-thymocyte (ATG) induction therapy

Petra Reinke / Charité – Universitätsmedizin Berlin / Berlin Institute of Health at Charité, Germany

LiveTreg Trial - A Phase I/IIa open label single ascending dose study to assess safety and tolerability of regulatory T cells to promote discontinuation of tacrolimus monotherapy in liver transplant recipients

Leila Amini / Charité – Universitätsmedizin Berlin, Germany

Advancing CD8+ Treg cell therapy to the clinic: The 8-Treg Trial

Carole Guillonneau / INSERM Nantes, France

TregTacRes Trial - An open-label, active-controlled single ascending dose, first-in-human study to investigate the safety and tolerability of TregTacRes as an adjunctive therapy in living-donor kidney recipients

Petra Reinke / Charité – Universitätsmedizin Berlin, Germany

Patient organization view on CGT regarding hope and concerns and expactations towards clinical scientists, regulatory authorithies and EU commission

Invited Speaker: Mónica Suengas, Juan Carlos Julián Mauro / EKPF European Kidney Patients Federation

Resetting autoimmunity in immune-mediated inflammatory disease

Invited Speaker: Gerhard Krönke / Charité – Universitätsmedizin Berlin, Germany

Treatment of type 1 diabetes with Tregs – towards marketing authorization

Invited Speaker: Piotr Trzonkowski / Medical University of Gdansk, Poland

Accelerate and de-risk EU ATMP development - Joint4ATMP

Invited Speaker: Annette Künkele / Charité – Universitätsmedizin Berlin, Germany

Health technology assessment – an important tool towards the market for ATMP´s

Catapult Cell and Gene Therapy, UK; tbc

Closing remarks

Abul Abbas, Spokesperson of the ReSHAPE EAB